KING OF PRUSSIA, Pa. — Dec. 12, 2017 — Independent observers have examined Genomind and, after thorough reviews, have recognized its unique platform, leadership and employees for their accomplishments in 2017.
Philadelphia Business Journal, for instance, presented Genomind President and CEO Michael Koffler with one of its Most Admired CEO Awards. The publication says it looks to highlight “men and women who are established leaders with a strong record of innovation in their field, outstanding financial performance, a commitment to quality, a strong vision, a commitment to diversity in the workplace and contributions to the Greater Philadelphia/New Jersey region.”
Koffler has led Genomind from its commercialization through its recent capital raising and expansion. He received his bachelor’s degree in finance from The George Washington University and an MBA from Harvard Business School.
Genomind has also been named to Deloitte’s 2017 Technology Fast 500, which recognizes the fastest growing technology, media, telecommunications, life sciences and energy technology companies in North America. The Technology Fast 500 is based on percentage of revenue growth from fiscal year 2013 to 2016.
In addition, The Philadelphia 100 selected Genomind for its merit-based program that highlights “companies that are among the fastest growing, privately-held companies…the integrity of the process and the resulting list makes the Philadelphia 100 one of the most sought awards in the region.” The Wharton Small Business Development Center and The Entrepreneurs’ Forum of Greater Philadelphia organize the honors.
Other highlights from 2017 include:
- The company launched G-DIG (the Genomind Drug Interaction Guide)®, which allows clinicians to better predict safety and efficacy before they prescribe medications for mental health treatment;
- Penguin Random House published “The Mind of God,” a widely praised book authored by Genomind Co-Founder Dr. Jay Lombard;
- Inc. 5000 named Genomind to its list of the fastest-growing private firms in America. It cited Genomind’s impressive 157 percent growth rate over three years; and
- Life Sciences Pennsylvania named Genomind its Emerging Company of the Year.
Koffler states that the year ahead promises further growth for Genomind into new markets and sectors that will benefit from the company’s established and unique platform.
Genomind is a personalized medicine company bringing innovation to mental healthcare through genetic testing. Genomind is comprised of pioneering researchers and thought leaders in psychiatry and neurology and specializes in pharmacogenetic laboratory testing for psychiatry. Genomind is committed to partnering with clinicians to improve their patients’ lives. Learn more at www.genomind.com